Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Net Income (2024 - 2025)

Kura Oncology (KURA) has disclosed Net Income for 2 consecutive years, with -$81.0 million as the latest value for Q4 2025.

  • Quarterly Net Income fell 370.95% to -$81.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$278.7 million through Dec 2025, down 62.05% year-over-year, with the annual reading at -$278.7 million for FY2025, 60.17% down from the prior year.
  • Net Income for Q4 2025 was -$81.0 million at Kura Oncology, down from -$74.1 million in the prior quarter.
  • The five-year high for Net Income was -$17.2 million in Q4 2024, with the low at -$81.0 million in Q4 2025.